Marshall Wace LLP Has $1.11 Million Stake in Surmodics, Inc. (NASDAQ:SRDX)

Marshall Wace LLP boosted its position in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 231.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,135 shares of the company's stock after purchasing an additional 19,635 shares during the quarter. Marshall Wace LLP owned 0.20% of Surmodics worth $1,114,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Oddo BHF Asset Management Sas acquired a new position in shares of Surmodics in the 3rd quarter valued at $6,593,000. Principal Financial Group Inc. acquired a new stake in shares of Surmodics during the third quarter worth about $1,190,000. JPMorgan Chase & Co. lifted its holdings in shares of Surmodics by 192.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 42,470 shares of the company's stock valued at $1,647,000 after purchasing an additional 27,960 shares in the last quarter. Barclays PLC grew its position in shares of Surmodics by 16.0% in the 3rd quarter. Barclays PLC now owns 88,750 shares of the company's stock valued at $3,443,000 after purchasing an additional 12,271 shares during the period. Finally, SG Americas Securities LLC increased its stake in Surmodics by 22.1% during the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company's stock worth $275,000 after purchasing an additional 1,255 shares in the last quarter. Institutional investors own 96.63% of the company's stock.

Wall Street Analyst Weigh In

SRDX has been the subject of several research analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. StockNews.com initiated coverage on Surmodics in a research note on Monday, February 3rd. They issued a "hold" rating on the stock. Finally, Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target on the stock in a report on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $43.00.

Surmodics Stock Down 0.6 %

Surmodics stock traded down $0.18 during mid-day trading on Monday, reaching $27.47. The company's stock had a trading volume of 8,574 shares, compared to its average volume of 277,139. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. Surmodics, Inc. has a 12 month low of $26.00 and a 12 month high of $42.44. The business's 50 day simple moving average is $29.43 and its 200 day simple moving average is $34.86. The company has a market capitalization of $392.72 million, a price-to-earnings ratio of -27.19 and a beta of 1.32.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The company had revenue of $28.09 million for the quarter, compared to analyst estimates of $32.23 million. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. As a group, research analysts anticipate that Surmodics, Inc. will post 0.2 earnings per share for the current year.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).